Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent -
31861-1.fp.png "SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal")
SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal
For the FITs | Antiplatelet Therapy For High Bleeding Risk Patients Undergoing PCI - American College of Cardiology
Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
Short and Optimal DAPT: Lessons From the EVOLVE SHORT-DAPT Late Breaking Science | tctmd.com
EVOLVE Short DAPT
Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention - ScienceDirect
See @DFCapodanno's Tweet on Twitter / Twitter
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
Synergy: Short DAPT Study - ppt download
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk | NEJM
Evolving Concepts in Post-PCI Antiplatelets Therapy - Kartik Pandurang Jadhav, Pankaj V. Jariwala, 2020
EVOLVE Short DAPT: A Single Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated with a Bioabsorbable Polymer- Ba
Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
EVOLVE Short DAPT in Print: P2Y12 Decisions Can Safely Be Made Case-by-Case | tctmd.com
Two further studies support three-month DAPT following PCI
Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT | tctmd.com
Dual antiplatelet therapy duration after percutaneous coronary intervention using drug eluting stents in high bleeding risk pati
EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com
Antiplatelet Therapy in High-Bleeding Risk Patients Undergoing PCI: Walking a Tightrope
SYNERGY™ Clinical Program - Short DAPT - Boston Scientific
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
Synergy: Short DAPT Study - ppt download
